预约演示

更新于：2025-05-07

METTL17

更新于：2025-05-07

基本信息

别名

False p73 target gene protein、FLJ20859、Methyltransferase 11 domain-containing protein 1

+ [5]

简介

Mitochondrial ribosome (mitoribosome) assembly factor (PubMed:36482135, PubMed:38199006). Binds at the interface of the head and body domains of the mitochondrial small ribosomal subunit (mt-SSU), occluding the mRNA channel and preventing compaction of the head domain towards the body (PubMed:36482135). Probable inactive methyltransferase: retains the characteristic folding and ability to bind S-adenosyl-L-methionine, but it probably lost its methyltransferase activity (PubMed:38234605).

关联

项与 METTL17 相关的药物

CpG-siRNAMETTL17

靶点

METTL17

作用机制

METTL17 inhibitors

在研机构

City of Hope National Medical Center

原研机构

City of Hope National Medical Center

在研适应症

急性髓性白血病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

WO2023183906

专利挖掘

靶点

METTL17

作用机制-

在研机构

The Broad Institute, Inc. [+1]

原研机构

The Broad Institute, Inc. [+1]

在研适应症

年龄相关疾病 [+2]

非在研适应症-

最高研发阶段药物发现

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 METTL17 相关的临床结果

登录后查看更多信息

100 项与 METTL17 相关的转化医学

登录后查看更多信息

0 项与 METTL17 相关的专利（医药）

登录后查看更多信息

项与 METTL17 相关的文献（医药）

2025-06-01·Toxicology and Applied Pharmacology

Demethylzeylasteral inhibits osteosarcoma cell proliferation by regulating METTL17-mediated mitochondrial oxidative phosphorylation

Article

作者: Cao, Jingyu ; Wang, Chengbo ; Aziz, Faisal ; Zhu, Xiangzhan ; Wang, Zimeng ; Li, Ya ; Zhang, Haotian ; Li, Xianxiao ; Yang, Minglei ; He, Lihua

Osteosarcoma (OS) represents the most common primary bone malignancy, characterized by substantial disability and mortality, thereby underscoring the critical need for more effective therapeutic interventions to improve clinical outcomes. Demethylzeylasteral (DEM) is a bio-active compound has been reported for its anti-tumor properties through various mechanisms. Nonetheless, the specific effects of DEM on OS have yet to be fully elucidated. This study demonstrated that DEM significantly inhibited OS cell proliferation both in vitro and in vivo. Mechanistically, DEM impairs mitochondrial OXPHOS by targeting METTL17, a known regulator of mitochondrial translation, resulting in reduced ATP production. Subsequent investigations revealed that METTL17 knockdown exerts potent anti-tumor effects in OS, significantly suppressing both in vitro cell proliferation and in vivo xenograft tumor growth. Furthermore, METL17 overexpression significantly alleviated the inhibitory effects of DEM on cell proliferation, while restoring ATP production and oxygen consumption rates. These findings suggest that DEM impedes OS growth by inducing mitochondrial dysfunction through targeting METTL17, thereby highlighting a novel therapeutic strategy and potential molecular target for OS treatment.

2025-02-01·Pharmacogenetics and Genomics

Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort

Article

作者: Rolla, Valeria C ; Sterling, Timothy R ; Andrade, Bruno B ; Yang, Jing ; Haas, David W ; Amorim, Gustavo ; Cordeiro-Santos, Marcelo ; Velez Edwards, Digna R ; Figueiredo, Marina C ; Jaworski, James ; Santos, Adalberto R ; Turner, Megan ; Kritski, Afrânio L

BackgroundGenetic polymorphisms have been associated with risk of antituberculosis treatment toxicity. We characterized associations with adverse events and treatment failure/recurrence among adults treated for tuberculosis in Brazil.MethodsParticipants were followed in Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil. We included persons with culture-confirmed drug-susceptible pulmonary tuberculosis who started treatment between 2015 and 2019, and who were eligible for pharmacogenetics. Treatment included 2 months of isoniazid, rifampin or rifabutin, pyrazinamide, and ethambutol, then 4 months of isoniazid and rifampin or rifabutin, with 24-month follow-up. Analyses included 43 polymorphisms in 20 genes related to antituberculosis drug hepatotoxicity or pharmacokinetics. Whole exome sequencing was done in a case-control toxicity subset.ResultsAmong 903 participants in multivariable genetic association analyses, NAT2 slow acetylator status was associated with increased risk of treatment-related grade 2 or greater adverse events, including hepatotoxicity. Treatment failure/recurrence was more likely among NAT2 rapid acetylators, but not statistically significant at the 5% level. A GSTM1 polymorphism (rs412543) was associated with increased risk of treatment-related adverse events, including hepatotoxicity. SLCO1B1 polymorphisms were associated with increased risk of treatment-related hepatoxicity and treatment failure/recurrence. Polymorphisms in NR1/2 were associated with decreased risk of adverse events and increased risk of failure/recurrence. In whole exome sequencing, hepatotoxicity was associated with a polymorphism in VTI1A, and the genes METTL17 and PRSS57, but none achieved genome-wide significance.ConclusionIn a clinical cohort representing three regions of Brazil, NAT2 acetylator status was associated with risk for treatment-related adverse events. Additional significant polymorphisms merit investigation in larger study populations, particularly regarding risk of treatment failure/recurrence.

2025-02-01·Journal of Biological Chemistry

Crucial role and conservation of the three [2Fe-2S] clusters in the human mitochondrial ribosome

Article

作者: Lill, Roland ; Boß, Linda ; Elsässer, Hans-Peter ; Stehling, Oliver

Mitochondria synthesize only a small set of their proteins on endogenous mitoribosomes. These particles differ in structure and composition from both their bacterial 70S ancestors and cytosolic 80S ribosomes. Recently published high resolution structures of the human mitoribosome revealed the presence of three [2Fe-2S] clusters in the small and large subunits. Each of these clusters is coordinated in a bridging fashion by cysteine residues from two different mitoribosomal proteins. Here, we investigated the cell biological and biochemical roles of all three iron-sulfur clusters in mitochondrial function and assembly. First, we found a requirement of both early and late factors of the mitochondrial iron-sulfur cluster assembly machinery for protein translation indicating that not only the mitoribosome [2Fe-2S] clusters but also the [4Fe-4S] cluster of the mitoribosome assembly factor METTL17 are required for mitochondrial translation. Second, siRNA-mediated depletion of the cluster-coordinating ribosomal proteins bS18m, mS25, or mL66 and complementation with either the respective WT or cysteine-exchange proteins unveiled the importance of the clusters for assembly, stability, and function of the human mitoribosome. As a consequence, the lack of cluster binding to mitoribosomes impaired the activity of the mitochondrial respiratory chain complexes and led to altered mitochondrial morphology with a loss of cristae membranes. Finally, in silico investigation of the phylogenetic distribution of the cluster-coordinating cysteine motifs indicated their presence in most metazoan mitoribosomes, with exception of ray-finned fish. Collectively, our study highlights the functional need of mitochondrial iron-sulfur protein biogenesis for both protein translation and respiratory energy supply in most metazoan mitochondria.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

生物医药百科问答

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。